H. D. Smith makes changes to executive leadership structure
Dale Smith, chairman and CEO of H. D. Smith Holding Co.
SPRINGFIELD, Ill. — H. D. Smith, an independent wholesaler and pharmaceutical brand support company, has announced a series of executive moves, including the appointment of Dale Smith as chairman and CEO of H. D. Smith Holding Co.
In his new role, Smith will oversee progress for all H. D. Smith business units, including wholesale distribution and specialty solutions. Smith previously served as chairman and CEO of H. D. Smith Wholesale Drug Co.
Additional executive moves include:
- Chris Smith, who served as president and COO for H. D. Smith Wholesale Drug Co., is now its president and CEO, with executive responsibility for the H. D. Smith wholesale distribution business unit, as well as the functional areas of information technology, human resources and finance, which support the entire company.
- Bob Appleby, previously SVP of category management at H. D. Smith Wholesale Drug Co., has been named president of H. D. Smith Specialty Solutions, which includes subsidiaries Smith Medical Partners and Triplefin. Transitioning into this role, he will be responsible for managing one of the company's fastest-growing business units as the nation seeks to shift health delivery closer to patients.
- Joe Conda joins the office of the chairman as EVP to focus on expanding upon the company's mission as an integrated provider of health products, solutions and services, a role that includes acquisitions and alliances. He was previously president of H. D. Smith Specialty Solutions.
Generic or brand-name prescription drugs? A Harris Poll examines Americans’ preference
NEW YORK — A new Harris Poll finds Americans favor generic prescription drugs over brand name products by a considerable margin.
Eighty-one percent of those who buy prescription drugs say they would purchase generics more often than brand-name drugs. A 42% subset goes so far as to assert that they would "always" choose to buy a generic drug. Older generations are especially likely to indicate that they would always go with generics (50% matures, 44% baby boomers, and 46% Gen X versus 33% millennials).
Meanwhile, 19% of those who purchase prescription drugs would more often choose to fill their script with the brand-name drug, and a mere 6% would "always" choose brand names. It is worth noting, however, that though majorities of adults both with and without children in their households favor generics, the minority preference for brand names is stronger among those with children in the household (24% with versus 17% without).
The Harris Poll was conducted among 2,255 U.S. adults surveyed online between Nov. 12 and 17, 2014.
When it comes down to the money
According to the findings, though an admittedly low percentage of generic drug buyers are unwilling to pay any out-of-pocket costs, the percentage has doubled in the past six years from 4% in 2008 to 8% now. Meanwhile, half (50%) of those who would buy generic drugs say they would be willing to pay $10 or less for a 30-day supply, 28% would pay between $10.01 and $25, and 11% would be open to out-of-pocket expenses between $25.01 and $50. Only 4% would shell out more than $50 to get their prescription filled with a generic.
Interestingly, millennials, men and those with children in their households are all more likely than their counterparts to say they would pay more than $10 out-of-pocket for generic prescription drugs.
- 52% of millennials versus 41% Gen Xers, 37% baby boomers and 38% matures
- 47% of men versus 38% of women
- 50% of adults with children in their households versus 40% of adults with no children in their households
Where to get the goods
Nine-in-10 adults buy prescription drugs (89%), but no single-purchase channel garners a majority of this business. However, a 32% plurality fills their prescriptions at chain drug stores. Meanwhile, nearly 2-in-10 of respondents said that they obtain prescription drugs at discount store pharmacies (17%), while more than 1-in-10 do so online or by mail order (14%) and at supermarket pharmacies (11%). Less than 10% visit local independent pharmacies (7%) and pharmacies at hospitals or medical centers (5%).
According to the survey, millennials are less likely than their elders to purchase prescription drugs at all (82% versus 91% Gen X, 92% baby boomers, and 96% matures). However, when they do need to fill a script, they and members of Gen X are most likely to do so at chain drug stores (41% millennials and 36% Gen X versus 24% each baby boomers and matures). In an interesting reversal, millennials — often noted for their more intense online presence as compared with their elders — are less likely than any other generation to obtain prescription drugs online or by mail order (3% millennials versus 13% Gen X, 21% baby boomers, and 26% matures).
Lupin to acquire remaining stake in South African generic drug maker
CAPE TOWN, South Africa — Pharma Dynamics has entered into an agreement with Lupin, in which Lupin will acquire the remaining 40% equity in Pharma Dynamics.
Financial terms of the deal were not disclosed.
“The transaction represents significant foreign investment into SA and is a major vote of confidence in the business. It will add additional global muscle to Pharma Dynamics’ operations and support the next phase of growth for the company. I have enjoyed an excellent relationship with Lupin, who has been a key partner in the business since 2008,” stated Paul Anley, CEO of Pharma Dynamics.
Added Vinita Gupta, CEO of Lupin, “We are delighted with this development as Africa is fast emerging as one of the growth engines of the future. We deeply appreciate the efforts of Mr. Paul Anley in building Pharma Dynamics into a very robust and the fastest growing Pharma major in the Republic of South Africa. We are very pleased that Paul Anley has agreed to continue as the CEO”.